To prevent recurrence of acute coronary syndrome (ACS), national practice guidelines recommend use of five-drug combination therapy. Our study assessed the proportion of patients discharged on all five medications following ACS and determined reasons for nonadherence. A retrospective, single-center chart review was conducted at a tertiary academic medical center. Patients 18 years and older who were admitted to the cardiac care unit with a diagnosis of ACS between January 2013 and January 2015 were included. Overall, 200 patients were screened and 155 were included in the study. Half of the patients received all guideline-recommended classes of pharmacological agents at discharge. The other half-78 patients-did not receive the five-drug combination, of whom 48 (62%) had reasons documented for nonadherence. Our study's findings suggest that rates of adherence need to improve given the clear benefits of these medications.
A cute coronary syndrome (ACS) remains a major cause of mortality worldwide due to recurrent cardiovascular events. This study aimed to review and document the current utilization and prescribing practices of pharmacotherapy for the secondary prevention of ACS in patients discharged from a cardiac care unit in a tertiary academic medical center.
METHODS
A retrospective, single-center chart review was conducted at State University of New York Upstate University Hospital. Patients 18 years and older who were admitted to the cardiac care unit with a diagnosis of ACS between January 2013 and January 2015 were included. Patients were excluded if they died during the hospitalization, transferred care to another hospital, or had a diagnosis other than ACS. Due to the retrospective retrieval of the data, informed consent was not obtained. Th e study did not off er any risks to the patients' confi dentiality and privacy.
Using a standardized collection form, the following demographic information was obtained: age at hospital admission, sex, and past medical history including hypertension, dyslipidemia, diabetes mellitus, coronary artery disease, and tobacco use. Reasons for nonadherence were also collected.
Statistical analyses were performed using SPSS version 23.0 (IBM Corp, Chicago, IL). Data were presented using descriptive statistics (mean ± standard deviation, median with interquartile range, or number with percentage). Categorical variables were compared using chi-square test for independence or Fisher exact test. Continuous variables were compared using the Student t test or Mann-Whitney U test. Odds ratios and 95% confidence intervals were calculated when applicable. All tests were two-tailed, and a P value < 0.05 was considered statistically signifi cant.
RESULTS
A total of 200 patients were initially screened, of whom 45 were excluded due to diagnoses other than ACS, transfer to other hospitals for higher level of care, or death during hospitalization (Figure 1 ). Baseline demographic and clinical characteristics are shown in Table 1 . No statistically signifi cant diff erences were noted between the adherent and nonadherent groups with respect to age, male gender, or past medical history.
Evaluation of medication compliance for secondary prevention of acute coronary syndrome Among the 155 ACS patients, 77 (50%) received all fi ve guideline-recommended medications at discharge. Overall, 95% of the study patients were prescribed aspirin; 92%, thienopyridine inhibitors; 67%, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs); 92%, beta-blockers; and 69%, high-intensity statins. Seventy-eight patients (50%) did not receive the fi ve-drug combination therapy at discharge. Th e absence of one of the fi ve agents does not necessarily imply lack of optimal treatment. A reason behind the nonadherence was documented for 48 patients (62.0%), as summarized in Table 2 .
DISCUSSION
Th is study demonstrates that the fi ve-drug regimen was provided to only half of the patients, leaving substantial room for improvement. However, it is also important to note that the individual prescription rates of the medications were encouraging. Observational studies provide valuable insight into treatment eff ectiveness and generalizability in routine practice (1) . Th is study has demonstrated that these lifesaving medications are being prescribed at suboptimal rates. Other studies have examined the proportion of hospitalized cardiac patients discharged on secondary prevention medications. One study conducted by Yetgin et al showed patients received aspirin, thienopyridine inhibitors, ACEI/ARBs, beta-blockers, statins, and combination therapy at rates of 94%, 100%, 80%, 87%, 96%, and 65%, respectively (2) . Another study demonstrated that only 27% of the patients received the combination of all fi ve agents (3).
Although 50% of the patients were not on all of the fi ve medications at discharge, this does not necessarily imply that the patients were treated suboptimally. In the present study, only 62.0% patients had a reasonable explanation for nonadherence. Documented reasons for nonadherence included hypotension, kidney disease, bradycardia, heart block, cocaine use, active liver disease, myalgia, gastrointestinal bleeding, and drug allergies. Beta-blockers have historically been underprescribed, likely due to adverse eff ects. One study with a rate of nonadherence to beta-blocker therapy similar to ours (6.8% vs 8%) documented the following reasons for nonadherence: sinus node disease/bradycardia (24.2%), hypotension (20.3%), airway disease (14.8%), congestive heart failure (11.7%), unknown (11.7%), other (7%), illicit drug use (6.2%), atrioventricular block (5.5%), depressed mood (0.8%), lightheadedness (0.8%), and fatigue (0.8%) (4). In order to overcome this barrier, patient education and outpatient follow-up to initiate beta-blocker therapy should be considered in all patients who do not have absolute contraindications.
Another underlying problem is compliance. Many studies have shown that patients are nonadherent to the prescribed regimens (1, 5, 6) . Premature discontinuation of therapy and prescription nonrenewals have been documented at rates of 33.3% and 75%, respectively (7) . Although a compliance rate of 100% would be ideal, certain preclusions exist. Inappropriate prescribing by physicians, adverse eff ects, contraindications, cost, and nonadherence in addition to other patient-specifi c factors must also be considered. Th e use of reinforcement programs to help aid in application of the guidelines, such as the CHAMP program, have been shown to improve prescription rates at discharge and demonstrated treatment persistence at 1-year follow-up (8) . Implementation of such programs may be benefi cial to ensure proper prescribing and help increase adherence rates.
One interesting fi nding of our study is the rate of prescribing inappropriate statin intensity. We believe this fi nding can be explained by changes in guidelines followed by a lag in physician response to such changes, such that some physicians may have still been targeting low-density lipoprotein levels based on previous recommendations. One study reviewed treatments at discharge and after 1 year in 6748 patients with a myocardial infarction and found that only 1 in 3 patients were prescribed an appropriate intensity statin and only 25% of patients were prescribed an increase in dosage after discharge (9) . Th e incidence of statin myopathy and transaminitis has been reported at rates of 1.5% to 5.0% (10) and 2% to 3%, respectively (11) . Although side eff ects may be a barrier to statin adherence, a number of physicians clearly are underprescribing statins at the correct dose. We would advise increasing the dose during patient follow-up; if a patient cannot tolerate a statin due to side eff ects, dose reductions or alternative nonstatin therapies should be considered rather than no treatment.
Our study had multiple limitations, including the small sample size and single center design. Evaluation of patients with reduced ejection fraction may have been benefi cial to assess appropriateness of noncompliance rates with ACEI therapy; however, the 2014 guidelines suggest there is evidence that ACEIs may be reasonable in all patients with cardiac or vascular disease (class IIb, level B) (12) . Th e external validity of the results may be limited, and caution must be taken when generalizing the fi ndings of our study. However, in order to better generalize the results, it is crucial to conduct more studies, including those in hospitals from areas all over the US. Furthermore, to meet benchmarks of quality care, management can be compared between diff erent institutions.
